Área Sanitaria de Santiago de Compostela e Barbanza
Área sanitaria
Novartis (Sweden)
Täby, SueciaPublicacións en colaboración con investigadores/as de Novartis (Sweden) (10)
2024
-
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study
The Lancet Haematology, Vol. 11, Núm. 3, pp. e206-e215
2023
-
Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours
British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1046-1055
2022
-
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115
2021
-
Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: Results from the REUMAVID study (phase 1)
RMD Open, Vol. 7, Núm. 1
-
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial
Rheumatology (United Kingdom), Vol. 60, Núm. 1, pp. 256-262
-
Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial
Annals of the Rheumatic Diseases, Vol. 80, Núm. 5, pp. 582-590
2013
-
Scientific competency questions as the basis for semantically enriched open pharmacological space development
Drug Discovery Today, Vol. 18, Núm. 17-18, pp. 843-852
-
Scientific requirements for the next-generation semantic web-based chemogenomics and systems chemical biology molecular information system OPS
Computational Chemogenomics (Pan Stanford Publishing Pte. Ltd.), pp. 213-242
2011
-
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study
BMC Musculoskeletal Disorders, Vol. 12
2010
-
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
Science Translational Medicine, Vol. 2, Núm. 52